The effect of probiotics on non-alcoholic fatty liver

Effect of Probiotics on elastographic findings of patients with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220104053626N1

Enrollment

Registered

2022-01-11

Start date

2021-02-28

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-alcoholic fatty liver disease diagnosed with ultrasound findings. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: In addition to their usual medications, Rifaximin 550 mg tablets will be given twice a day for a week after one week of probiotics containing a combination of Lacto

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Age 18 to 59 years Willingness to participate in the study No history of alcohol consumption Do not take drugs with liver toxicity

Exclusion criteria

Exclusion criteria: Having liver disease with specific etiologies such as viral hepatitis Cirrhosis of the liver alcohol consumption Pregnancy and lactation Take other nutritional supplements Recent 3 months of antibiotic use

Design outcomes

Primary

Measure	Time frame
Determination of the effect of probiotics on hepatic steatosis in patients with non-alcoholic fatty liver disease in comparison with the control group. Timepoint: After completing 6 months of treatment, patients will undergo elastography again and the degree of stasis will be determined based on LSM and CAP criteria. Pre- and post-intervention findings will be compared. Method of measurement: After treatment, patients will undergo elastography again and the degree of stasis will be determined based on LSM and CAP criteria. Pre- and post-intervention findings will be compared.;Determination of the effect of probiotics on hepatic fibrosis in patients with non-alcoholic fatty liver disease in comparison with the control group. Timepoint: After completing 6 months of treatment, patients undergo elastography again and the degree of their liver fibrosis will be determined based on LSM and CAP criteria. The findings before and after the intervention will be compared. Method of measurement: After completing the treatment, the patients will undergo elastography again and their degree of liver fibrosis will be determined according to LSM and CAP criteria. The findings before and after the intervention will be compared.	—

Measure

Time frame

Determination of the effect of probiotics on hepatic steatosis in patients with non-alcoholic fatty liver disease in comparison with the control group. Timepoint: After completing 6 months of treatment, patients will undergo elastography again and the degree of stasis will be determined based on LSM and CAP criteria. Pre- and post-intervention findings will be compared. Method of measurement: After treatment, patients will undergo elastography again and the degree of stasis will be determined based on LSM and CAP criteria. Pre- and post-intervention findings will be compared.;Determination of the effect of probiotics on hepatic fibrosis in patients with non-alcoholic fatty liver disease in comparison with the control group. Timepoint: After completing 6 months of treatment, patients undergo elastography again and the degree of their liver fibrosis will be determined based on LSM and CAP criteria. The findings before and after the intervention will be compared. Method of measurement: After completing the treatment, the patients will undergo elastography again and their degree of liver fibrosis will be determined according to LSM and CAP criteria. The findings before and after the intervention will be compared.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasood Dinevari

Tabriz University of Medical Sciences

dinvarim@tbzmed.ac.ir+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026